Singapore markets closed
Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,856.56 -1,938.04 (-3.09%) CMC Crypto 200
1,261.13 -96.88 (-7.13%)
Wilmar International Limited (F34.SI)
SES - SES Delayed price. Currency in SGD
Add to watchlist
At close: 05:11PM SGT
| Previous close | 3.1700 |
| Open | 3.1800 |
| Bid | 3.1700 x 0 |
| Ask | 3.1800 x 0 |
| Day's range | 3.1600 - 3.2000 |
| 52-week range | 3.0700 - 4.1000 |
| Volume | |
| Avg. volume | 5,403,064 |
| Market cap | 19.852B |
| Beta (5Y monthly) | 0.52 |
| PE ratio (TTM) | 9.64 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.17 (5.35%) |
| Ex-dividend date | 29 Apr 2024 |
| 1y target est | N/A |
- PR Newswire
Cerecin forges strategic partnership with A*STAR's Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders.
Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, is pleased to announce the establishment of a Memorandum of Understanding (MOU) with A*STAR's Institute of Molecular and Cell Biology (IMCB). This collaboration aims to accelerate research and treatment initiatives for neurological disorders and diseases to enhance overall health and brain function.
© 2024 Yahoo. All rights reserved.